Kiltearn Partners LLP Purchases Shares of 345,471 CVS Health Corporation $CVS

Key Points

• Kiltearn Partners LLP acquired 345,471 CVS Health shares worth approximately $35.7 million, making CVS its second-largest portfolio holding at 8.7%. Institutional investors collectively own 80.66% of the company.
• CVS reported stronger-than-expected quarterly results, with earnings of $2.58 per share versus the $1.87 consensus and revenue of $106.1 billion. The company raised or maintained fiscal 2026 guidance at $7.90–$8.10 EPS.
• CVS pays a quarterly dividend of $0.665 per share, equating to a $2.66 annualized payout and a 2.9% yield. Analysts maintain a “Moderate Buy” consensus rating with an average price target of $107.17.

Kiltearn Partners LLP acquired a new position in shares of CVS Health Corporation (NYSE:CVS - Free Report) during the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 345,471 shares of the pharmacy operator's stock, valued at approximately $35,739,000. CVS Health makes up approximately 8.7% of Kiltearn Partners LLP's investment portfolio, making the stock its 2nd biggest position.

Other institutional investors have also modified their holdings of the company. BlackRock Inc. purchased a new position in shares of CVS Health in the 2nd quarter valued at $12,747,462,000. Norges Bank purchased a new stake in shares of CVS Health in the 4th quarter valued at about $1,666,265,000. Wellington Management Group LLP lifted its holdings in shares of CVS Health by 193.2% in the 4th quarter. Wellington Management Group LLP now owns 18,564,392 shares of the pharmacy operator's stock valued at $1,473,270,000 after purchasing an additional 12,233,675 shares during the last quarter. Pzena Investment Management LLC acquired a new stake in shares of CVS Health in the 2nd quarter valued at about $1,217,558,000. Finally, Bank of New York Mellon Corp purchased a new position in CVS Health during the 2nd quarter worth approximately $932,454,000. Hedge funds and other institutional investors own 80.66% of the company's stock.

CVS Health Stock Performance

NYSE:CVS opened at $93.01 on Friday. The company has a debt-to-equity ratio of 0.74, a current ratio of 0.87 and a quick ratio of 0.66. The firm has a market cap of $118.96 billion, a price-to-earnings ratio of 24.61, a price-to-earnings-growth ratio of 0.85 and a beta of 0.61. The firm's fifty day moving average price is $102.02 and its 200 day moving average price is $88.86. CVS Health Corporation has a 1-year low of $69.51 and a 1-year high of $110.68.

CVS Health (NYSE:CVS - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The pharmacy operator reported $2.58 EPS for the quarter, topping analysts' consensus estimates of $1.87 by $0.71. The company had revenue of $106.10 billion during the quarter, compared to the consensus estimate of $100.03 billion. CVS Health had a net margin of 1.18% and a return on equity of 13.12%. CVS Health's quarterly revenue was up 7.3% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.81 EPS. CVS Health has set its FY 2026 guidance at 7.900-8.100 EPS. On average, sell-side analysts expect that CVS Health Corporation will post 8.02 EPS for the current year.

CVS Health Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Monday, August 3rd. Shareholders of record on Thursday, July 23rd were given a dividend of $0.665 per share. The ex-dividend date was Thursday, July 23rd. This represents a $2.66 annualized dividend and a yield of 2.9%. CVS Health's payout ratio is presently 70.37%.

Analysts Set New Price Targets

A number of brokerages have weighed in on CVS. Deutsche Bank Aktiengesellschaft boosted their price objective on CVS Health from $88.00 to $92.00 and gave the company a "buy" rating in a research note on Thursday, May 7th. Wells Fargo & Company lifted their target price on shares of CVS Health from $103.00 to $123.00 and gave the company an "overweight" rating in a report on Monday, July 13th. Mizuho upped their price target on shares of CVS Health from $110.00 to $115.00 and gave the company an "outperform" rating in a research report on Monday, June 8th. Piper Sandler reissued an "overweight" rating and set a $113.00 price objective on shares of CVS Health in a research report on Monday, June 1st. Finally, Argus lifted their price objective on shares of CVS Health from $104.00 to $114.00 and gave the company a "buy" rating in a research note on Wednesday. Twenty-two equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the stock. According to MarketBeat, CVS Health presently has an average rating of "Moderate Buy" and a consensus target price of $107.17.

CVS Health Company Profile

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.

Want to see what other hedge funds are holding CVS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CVS Health Corporation (NYSE:CVS - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source